title: Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
abstract: OBJECTIVE
  Small-molecule insulin-like growth factor-I receptor (IGF-IR)-specific tyrosine kinase inhibitors have been recently proposed as clinically viable approaches to impair IGF-IR functions. NVP-AEW541 seems one of the most promising agents. In this article, we point out its effects against migration, metastasis, vasculogenicity, and angiogenesis of Ewing's sarcoma cells.
  
  
  METHODS
  In vivo NVP-AEW541 effectiveness was analyzed against TC-71 Ewing's sarcoma growth and bone metastasis after cell inoculation in athymic mice. Activity of the compound against angiogenesis as well as vasculogenesis properties was also considered both in vitro and in xenografts. Serum glucose, urea, transaminase levels, as well as other signs of distress were checked in mice treated with the IGF-IR inhibitor.
  
  
  RESULTS
  Significant inhibition of migration, metastasis, vasculogenicity, and angiogenesis was recorded after treatment of Ewing's sarcoma cells with NVP-AEW541. In view of its application and the similarity of insulin receptor and IGF-IR, diabetogenic side effects were considered. We observed a significant decrease of glucose blood serum due to increased glucose uptake at cellular level and an increase in urea concentration. Moreover, an initial weight loss was observed in mice bearing tumors. All these side effects were similarly detected in mice treated with vincristine. After the first days of treatment, all the animals started to grow again.
  
  
  CONCLUSIONS
  Our results globally reinforce the idea that IGF-IR inhibitor NVP-AEW541 could have a role in future combined therapies and suggest to pursue a thorough molecular analysis of the metabolic activity of IGF-IR to avoid possible side effects of these inhibitors.
authors.affiliation: Laboratory of Oncologic Research, Istituti Ortopedici Rizzoli, Bologna, Italy.
authors.forename: Maria C
authors.initials: MC
authors.lastname: Manara
authors.forename: Lorena
authors.initials: L
authors.lastname: Landuzzi
authors.forename: Patrizia
authors.initials: P
authors.lastname: Nanni
authors.forename: Giordano
authors.initials: G
authors.lastname: Nicoletti
authors.forename: Diana
authors.initials: D
authors.lastname: Zambelli
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Lollini
authors.forename: Cristina
authors.initials: C
authors.lastname: Nanni
authors.forename: Francesco
authors.initials: F
authors.lastname: Hofmann
authors.forename: Carlos
authors.initials: C
authors.lastname: García-Echeverría
authors.forename: Piero
authors.initials: P
authors.lastname: Picci
authors.forename: Katia
authors.initials: K
authors.lastname: Scotlandi
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D011743:Pyrimidines / Q000494:pharmacology*; D011758:Pyrroles / Q000494:pharmacology*; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012512:Sarcoma, Ewing / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
chemical_list: C501177:NVP-AEW541; D011743:Pyrimidines; D011758:Pyrroles; D017526:Receptor, IGF Type 1